Evidence map›Paper›PMID 26350228›Full record

ArticleEuropean journal of pediatrics2016

Diagnostic and management practices for phenylketonuria in 19 countries of the South and Eastern European Region: survey results.

Maria Giżewska, Anita MacDonald, Amaya Bélanger-Quintana, Alberto Burlina, Maureen Cleary, Turgay Coşkun, François Feillet, Ania C Muntau, Friedrich K Trefz, Francjan J van Spronsen and 1 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in European journal of pediatrics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 73 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 7 countries.

Maria GiżewskaDepartment of Pediatrics, Endocrinology, Diabetology, Metabolic Diseases and Cardiology, Pomeranian Medical University, 71-252 Szczecin; Unii Lubelskiej 1, Szczecin, Poland. maria.gizewska@gmail.com.
Anita MacDonaldDepartment of Dietetics, The Children's Hospital, Birmingham, UK. Anita.Macdonald@bch.nhs.uk.
Amaya Bélanger-QuintanaHospital Ramon y Cajal, Madrid, Spain. amaya.belanger@salud.madrid.org.
Alberto BurlinaDepartment of Pediatrics, University Hospital, Padova, Italy. alberto.burlina@unipd.it.
Maureen ClearyDepartment of Metabolic Medicine, Great Ormond Street Hospital, London, UK. maureen.cleary@gosh.nhs.uk.
Turgay CoşkunDepartment of Pediatrics, Division of Pediatric Nutrition and Metabolism, Hacettepe University Faculty of Medicine, Hacettepe, Ankara, Turkey. drturgaycoskun@gmail.com.
François FeilletHôpital d'Enfants, CHU Brabois, Vandoeuvre-lès-Nancy, France. f.feillet@chu-nancy.Fr.
Ania C MuntauUniversity Children's Hospital, University Medical Center Hamburg Eppendorf, Hamburg, Germany. muntau@uke.de.
Friedrich K TrefzUniversity Children's Hospital, Heidelberg, Germany. friedrich.trefz@gmx.de.
Francjan J van SpronsenDepartment of Paediatrics, University of Groningen, Groningen, The Netherlands. f.j.van.spronsen@umcg.nl.
Nenad BlauDietmar-Hopp Metabolic Center, University Children's Hospital, Heidelberg, Germany. Nenad.Blau@med.uni-heidelberg.de.
Birmingham Children's Hospital · GBCentre Hospitalier Régional et Universitaire de Nancy · FRGreat Ormond Street Hospital · GBHacettepe University Hospital · TRHeidelberg University · DEHospital Universitario Ramón y Cajal · ESPomeranian Medical University · PLUniversität Hamburg · DEUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To avoid potentially severe outcomes, phenylketonuria (PKU) must be detected as soon as possible after birth and managed with life-long treatment. A questionnaire-based survey was performed to document diagnosis and management practices for PKU in a region of Southern and Eastern Europe. Prevalence and management data were obtained from 37/59 (63 %) centres within 19/22 (86%) contacted countries (N = 8600 patients). The main results' analysis was based on completed questionnaires obtained from 31 centres (53%) within 15 countries (68%). A median of 10 % of patients per centre had been diagnosed after the newborn period. Metabolic dieticians and specialised adult PKU clinics were lacking in 36 and 84% of centres, respectively. In 26% of centres, treatment initiation was delayed until >15 days of life. Blood phenylalanine (Phe) thresholds to start treatment and upper Phe targets were inconsistent across centres. Ten percent of centres reported monitoring Phe every 2 weeks for pregnant women with PKU, which is insufficient to minimise risk of neonatal sequalae. Sapropterin dihydrochloride treatment was available in 48% of centres, with 24-h responsiveness tests most common (36%). Only one centre among the five countries lacking newborn screening provided a completed questionnaire.

conclusionTargeted efforts by health care professionals and governments are needed to optimise diagnostic and management approaches for PKU in Southern and Eastern Europe. WHAT IS KNOWN: PKU must be detected early and optimally managed throughout life to avoid poor outcomes, yet newborn screening is not universal and diagnostic and management practices for PKU are known to vary widely between different centres and countries. Targeted efforts by health care professionals and governments are needed to optimise diagnostic and management approaches. WHAT IS NEW: PKU management practices are documented in 19 South and Eastern European countries indicating a heterogeneous situation across the region. Key areas for improvement identified in surveyed centres include a need for comprehensive screening in all countries, increased number of metabolic dietitians and specialised adult PKU clinics, delayed time to treatment initiation, appropriate Phe thresholds, Phe targets and monitoring frequencies, and universal access to currently available treatment options.

Indexed as

AdolescentAdultChildChild, PreschoolDisease ManagementEuropeFemaleHealth PersonnelHumansInfantInfant, NewbornNeonatal ScreeningPhenylalaninePhenylketonuriasPregnancySurveys and QuestionnairesPhenylalanineDiagnosisManagementPhenylketonuriaQuestionnaireSapropterin dihydrochlorideScreeningSurveyTetrahydrobiopterin

Identifiers

PMID26350228
PMCPMC4724370
OpenAlexW1768920169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.